A practical reference on research peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-19. Anything still debated is marked as such rather than presented as settled.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Although Parsons had said he wanted his body cremated at Joshua Tree and his ashes spread over the formation Cap Rock, Parsons' stepfather organized a private ceremony in New Orleans and left the body in the care of a funeral home. But, to fulfill Parsons' wishes, Kaufman and a friend stole both a hearse and his body and drove it to Joshua Tree. At Cap Rock Parking Lot, they poured gasoline into the open coffin and lit it, creating an enormous fireball. They were arrested and eventually fined $750 for stealing the coffin. What remained of Parsons' body was buried in Garden of Memories Cemetery in Metairie, Louisiana. The story brings Parsons fans out to a large rock flake informally known to rock climbers as the Gram Parsons Memorial Hand Traverse. At some point, someone added a slab that marked Parsons' cremation to the memorial rock; that slab was removed by the US National Park Service and moved to the Joshua Tree Inn. Joshua Tree park guides are given the option to tell the story of Parsons' cremation during tours, but there is no mention of the act in official maps or brochures.
=== General information === "Pakistan". The World Factbook (2025 ed.). Central Intelligence Agency. Pakistan from UCB Libraries GovPubs Pakistan from BBC News Wikimedia Atlas of Pakistan Key Development Forecasts for Pakistan from International Futures Geographic data related to Pakistan at OpenStreetMap
=== Generic names === Topilutamide is the generic name of the drug and its INNTooltip International Nonproprietary Name. It is also known more commonly as fluridil. Topilutamide is also known by its former developmental code name BP-766.
To convert this to the real range on the ground, the plotter used basic trigonometry on a right angle triangle; the slant range was the hypotenuse and the open angle was the measurement from the radiogoniometer. The base and opposite sides could then be calculated, revealing the distance and altitude. An important correction was the curvature of the Earth, which became significant at the ranges CH worked at. Once calculated, this allowed the range to be properly plotted, revealing the grid square for the target, which was then reported up the chain. When the target was first detected at long range, the signal typically did not have enough of a return in the second lobe to perform height finding. This only became possible as the aircraft approached the station. Eventually this problem would recur as the target centred itself in the second lobe, and so forth. Additionally, it was not possible to determine the difference between a signal being compared between the first and second or second and third lobe, which caused some ambiguity at short ranges. However, as the altitude was likely determined long before this, this tended not to be a problem in practice. This pattern left a set of distinct angles where reception in both lobes was very low. To address this, a second set of receiver antennas was installed at 45 feet (14 m). When the lower antennas were used, the pattern was shifted upward, providing strong reception in the "gaps", at the cost of diminished long-range reception due to the higher angles.
=== Sources === Fulbrook, Mary (1991). A Concise History of Germany. Cambridge University Press. ISBN 978-0-521-36836-0. Murdoch, Adrian (2004). "Germania Romana". In Murdoch, Brian; Read, Malcolm (eds.). Early Germanic Literature and Culture. Boydell & Brewer. pp. 55–73. ISBN 1-57113-199-X.
Sources: en.wikipedia.org
In reconstructive rhinoplasty, the defects and deformities that the plastic surgeon encounters, and must restore to normal function, form, and appearance include broken and displaced nasal bones; disrupted and displaced nasal cartilages; a collapsed bridge of the nose; congenital defect, trauma (blunt, penetrating, blast), autoimmune disorder, cancer, intranasal drug-abuse damages, and failed primary rhinoplasty outcomes. Rhinoplasty reduces bony humps, and re-aligns the nasal bones after they are cut (dissected, resected). When cartilage is disrupted, suturing for re-suspension (structural support), or the use of cartilage grafts to camouflage a depression allow the re-establishment of the normal nasal contour of the nose for the patient. When the bridge of the nose is collapsed, rib-cartilage, ear-cartilage, or cranial-bone grafts can be used to restore its anatomic integrity, and thus the aesthetic continuity of the nose. For augmenting the nasal dorsum, autologous cartilage and bone grafts are preferred to (artificial) nose prostheses, because of the reduced incidence of histologic rejection and medical complications.
=== Discovery of the role of yeast === The French chemist Louis Pasteur founded zymology in 1856 when he connected yeast to fermentation. In studying the conversion of sugar to alcohol by yeast, Pasteur concluded that the fermentation was catalyzed by a vital force, called "ferments", within the yeast cells. The "ferments" were thought to function only within living organisms. Pasteur wrote that "Alcoholic fermentation is an act correlated with the life and organization of the yeast cells, not with the death or putrefaction of the cells."
=== Backwashing === In backwashing, the transmembrane pressure is periodically inverted by the use of a secondary pump, so that permeate flows back into the feed, lifting the fouling layer from the surface of the membrane. Backwashing is not applicable to spirally wound membranes and is not a general practice in most applications. (See Clean-in-place)
=== brGDGT === The building blocks of brGDGT, specifically the long alkyl groups (iso-diabolic acid), are detected in acidobacteria subdivisions 1, 3, 4, and 6. Small amounts of brGDGT-I was detected in Acidobacteriaceae strain A2-4c by full mass spectrum and tentatively in Acidobacteriaceae strain 307 by single-ion monitoring MS; none has been detected in the 44 other strains tested as of 2018. More complex brGDGTs known from nature have not yet been detected in any cell culture.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.